Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials

Vaxcyte Inc. (NASDAQ:PCVX) is one of the best stocks to buy and hold for the next 6 months. On February 11, Vaxcyte Inc. (NASDAQ:PCVX) confirmed the dosing of the first participants in its OPUS-3 Phase 3 trial. The trial is evaluating the VAX-31 pneumococcal conjugate vaccine in adults who previously received pneumococcal vaccination.

VAX-31 is a candidate 31-valent pneumococcal conjugate vaccine designed to cover approximately 95% of invasive pneumococcal disease. The biotechnology company plans to enroll 720 healthy US adults aged 50 and older who have previously received pneumococcal vaccination into the trial.

The company is optimistic about topline data from the OPUS-3 and OPUS-2 trials in the first half of 2027. The US Food and Drug Administration has already granted VAX-31 Breakthrough Therapy designation for the use of the vaccine in pneumococcal disease and pneumonia caused by Streptococcus pneumoniae.

Earlier on February 2, Vaxcyte closed a $632.5 million public offering following the sale of 12.65 million shares. The new capital injection positions the company in a solid financial position to advance the development of VAX-31, a 31-valent pneumococcal conjugate vaccine.

Vaxcyte Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology company developing engineered, high-fidelity vaccines to treat and prevent bacterial infections. Using a proprietary cell-free protein synthesis platform, it develops vaccines targeting complex, hard-to-treat diseases, with a primary focus on pneumococcal conjugate vaccines (PCVs) for adults and infants.

READ NEXT: 11 Best High Return Penny Stocks to Buy Right Now and 10 High-Growth Low PE Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.